



#5/1308
7/16/01
Atty Dkt APP 37.20
PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Missing Parts, Commissioner for Patents, Washington, D.C. 20231 on March 27, 2001.

March 27, 2001 Jamie Befort
Date Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Scott UMLAUF.

Serial No.: 09/705,022

Art Unit: Unassigned

Filing Date: 1 November 2000

Examiner: Unassigned

Title: NUCLEIC ACID VACCINE COMPOSITIONS
HAVING A MAMMALIAN CD80/CD86 GENE
PROMOTER DRIVING ANTIGEN EXPRESSION

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Box Missing Parts
Commissioner for Patents
Washington, D.C. 20231

Sir:

The information listed below may be material to the examination of the above-identified application. Copies of the information and completed PTO-1449 forms are submitted herewith. The Examiner is respectfully requested to make this information of official record in the application. The information includes:

United States Patent No. 4,945,050, to Sanford, issued July 31, 1990;

United States Patent No. 5,100,792, to Sanford et al., issued March 31, 1992;

United States Patent No. 5,120,657, to McCabe et al., issued June 9, 1992;

United States Patent No. 5,149,655, to McCabe, issued Sept. 22, 1992;


United States Patent No. 5,187,077, to Gearing et al., issued Feb. 16, 1993;

United States Patent No. 5,204,253, to Sanford, issued April 20, 1993;
United States Patent No. 5,584,807, to McCabe, issued Dec. 17, 1996;
United States Patent No. 5,589,466, to Felgner et al., issued Dec. 31, 1996;
United States Patent No. 5,630,796, to Bellhouse et al., issued May 20, 1997;
United States Patent No. 5,738,852, to Robinson et al., issued April 14, 1998;
United States Patent No. 5,865,796, to McCabe, issued Feb. 2, 1999;
United States Patent No. 6,168,587, to Bellhouse et al., issued Jan. 2, 2001;
United States Patent No. 6,194,389, to Johnston et al., issued Feb. 27, 2001;
International Publication No. WO 94/24263, published Oct. 27, 1994;
International Publication No. WO 96/04947, published Feb. 22, 1996;
International Publication No. WO 96/12513, published May 2, 1996;
International Publication No. WO 96/14855, published May 23, 1996;
International Publication No. WO 96/20022, published July 4, 1996;
International Publication No. WO 97/32987, published Sept. 12, 1997;
International Publication No. WO 97/48485, published Dec. 24, 1997;
International Publication No. WO 98/10750, published March 19, 1998;
Morgan et al. (1976) *Science* 193:1007-1008;
Schuler et al. (1985) *J. Exp. Med.* 161:526;
Brankenhoff et al. (1987) *Immunol.* 139:4116-4121;
Romani et al. (1989) *J. Invest. Dermatol.* 93:600;
Schwartz R.H. (1990) *Science* 248:1349-1356;
Van Seventer, G.A. (1990) *J. Immunol.* 144:4579-4586;
Jenkins M.K. (1992) *Immunol. Today* 13:69-73;
Schwartz R.H. (1992) *Cell* 71:1065-1068;
Liu Y. et al. (1992) *J. Exp. Med.* 175:437-445;
Nabavi et al. (1992) *Nature* 360:266-268;
Spriggs et al., (1992) *J. Exp. Med.* 176:1543-1550;
Spriggs (1992) *Immunol Ser.* 56:3-34;
Armitage et al. (1992) *Nature* 357:80-82;
Naujokas M.F., et al. (1993) *Cell* 74:257-268;

Freeman et al. (1993) *Science* 262:909-911;
Selvakumar et al. (1993) *Immunogenetics* 38:292-295;
Lyman et al. (1995) *Oncogene* 11(6):1165-72;
Ellis et al. (1996) *J. Immunol.* 56:2700-2709;
Zhang et al. (1996) *Gene* 183:1-6;
Fong et al. (1996) *J. Immunol.* 157:4442-4450;
Wong et al. (1997) *J. Exp. Med.*, 186:2075-2080;
Wong et al. (1997) *J Biol Chem* 272(40):25190-4;
Gurunathan et al. (1998) *J. Immunol.*, 161:4563-4571;
Pulendran et al. (1998) *J. Exp. Med.*, 188:2075-2082;
Wong et al. (1999) *J. Immunol* 162:2251-2258; and
Josien et al. (1999) *J. Immun.* 162:2562-2568.

This Information Disclosure Statement under 37 CFR § 1.97(b) is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Respectfully submitted,

By: 
Thomas P. McCracken
Registration No. 38,548

POWDERJECT TECHNOLOGIES, INC.
6511 Dumbarton Circle
Fremont, CA 94555
Telephone: (510) 742-9700, extension 209
Fax: (510) 742-9720